Esophageal Cancer Systemic Therapy

Scope and treatment selection

Systemic therapy should be selected according to resectability, anatomic extent, treatment intent, histology, prior therapy, nutritional status, and the feasibility of surgery or radiotherapy. The available evidence in these references is heterogeneous: randomized trials and meta-analyses inform perioperative and advanced-disease treatment, whereas several studies are retrospective, exploratory, or protocol reports and should not be interpreted as definitive comparative evidence.^{[2]A1a[3]A1a[7]B2b[9]A1b[10]B2b[17]A1b[20]B3b}

Resectable, locally advanced disease

For patients proceeding to curative-intent esophagectomy, neoadjuvant treatment is the principal systemic-therapy setting represented by the cited evidence. A meta-analysis of three randomized trials involving 375 patients found that neoadjuvant chemoradiotherapy (nCRT) produced higher R0-resection and pathological complete-response rates than neoadjuvant chemotherapy (nCT), but did not significantly improve 3- or 5-year progression-free or overall survival.^[3]A1a Thus, nCRT may be favored when maximizing tumor regression, margin-negative resection, or pathological response is the immediate objective, while the survival advantage over nCT remains unproven in this pooled analysis.^[3]A1a

Treatment tolerance and nutritional trajectory should be assessed during neoadjuvant therapy. In an exploratory analysis of the OGSG1003 randomized phase-II dataset in locally advanced esophageal squamous cell carcinoma, weight loss during neoadjuvant chemotherapy was evaluated in relation to postoperative infectious complications and prognosis; tumor stenosis and treatment adverse events were recognized contributors to weight loss.^[7]B2b This supports active nutritional and functional monitoring rather than treating systemic therapy as an isolated anticancer intervention.^[7]B2b

After curative R0 resection, adjuvant systemic therapy remains regimen- and population-dependent. In a randomized phase-II study of 62 patients with node-positive esophageal squamous cell carcinoma, adjuvant leucovorin/5-fluorouracil (LV5FU2) was compared with LV5FU2 plus oxaliplatin (FOLFOX), with disease-free survival as the primary endpoint; the study specifically addressed the unresolved optimal perioperative approach.^[8]B2b Retrospective evidence in 125 patients with stage IIB–IVA disease evaluated postoperative concurrent chemoradiotherapy: 97.6% received more than 50 Gy, but only 41.6% received more than five weeks of chemotherapy, illustrating the importance of completion and tolerability when postoperative chemoradiation is used.^[16]A1b

Locally advanced unresectable disease

For locally advanced unresectable thoracic squamous-cell carcinoma, definitive chemoradiotherapy with cisplatin plus 5-fluorouracil was identified as the contemporary standard in the JCOG1510/TRIANgLE phase-III protocol.^[9]A1b The trial was designed to test whether induction docetaxel, cisplatin, and 5-fluorouracil followed by conversion surgery or definitive chemoradiotherapy improves overall survival compared with definitive chemoradiotherapy alone; because the cited report describes the trial design, it does not establish superiority of the induction strategy.^[9]A1b

Radiotherapy-related toxicity may require supportive management. In a randomized trial of 60 patients with esophageal or gastric-cardia cancer receiving chemoradiotherapy, oral famotidine 40 mg daily, administered four hours before each radiation session, was compared with placebo to assess hematologic complications.^[6]A1b The intervention should therefore be regarded as an investigated supportive-care strategy, not as established anticancer systemic therapy.^[6]A1b

Unresectable advanced or metastatic disease

For previously untreated advanced esophageal cancer, pembrolizumab plus chemotherapy is the key first-line immunochemotherapy setting represented here. The Japanese subgroup of KEYNOTE-590 received pembrolizumab 200 mg every three weeks for up to 35 cycles or placebo, combined with cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day; the five-year analysis used a July 10, 2023 data cutoff and followed participants with overall and progression-free survival, response, and safety endpoints.^[4]A1b A Japanese cost-effectiveness model likewise evaluated pembrolizumab plus chemotherapy versus chemotherapy alone from the healthcare-payer perspective, including a programmed-death-ligand 1 combined positive score subgroup of CPS ≥10.^[5]A1b

After progression, second-line nivolumab monotherapy has real-world activity in unresectable or metastatic disease. In a multicenter cohort of 184 patients, the response rate among 128 patients with measurable lesions was 23%, disease control for the full cohort was 45%, and grade ≥3 adverse events occurred in 14%, with no treatment-related deaths reported.^[10]B2b These outcomes support nivolumab as a reasonable post-first-line option when clinically appropriate, while recognizing the nonrandomized design.^[10]B2b

Other investigational or nonstandard systemic approaches should not displace evidence-supported therapy. In a phase-II study of pretreated advanced squamous carcinoma, the PI3K inhibitor BKM120 yielded stable disease in 20 of 42 patients and confirmed partial response in 2 patients.^[13]B2b A randomized study of Xiaoaiping plus S-1/cisplatin enrolled 124 patients with advanced disease and compared the combination with S-1/cisplatin alone, but the cited information does not provide sufficient outcome detail to establish routine use.^[17]A1b

Oligometastatic and recurrent disease

Oligometastatic esophagogastric cancer requires multidisciplinary assessment rather than automatic systemic therapy alone. A systematic review and meta-analysis evaluated definitions based on the maximum number of involved organs and lesions per organ and compared metastasectomy or stereotactic radiotherapy with systemic therapy alone; the review’s purpose was to determine whether local oligometastasis-directed treatment may improve overall survival, but definitions were heterogeneous across studies.^[2]A1a

For locally recurrent disease after definitive chemoradiotherapy, salvage photodynamic therapy with talaporfin sodium has been evaluated, including lesions exceeding the original clinical-trial boundaries of luminal circumference ≤1/2, longitudinal length ≤3 cm, and absence of cervical-esophageal invasion.^[19]C4 Because the expanded-indication study was retrospective and included 34 consecutive patients, salvage PDT should be individualized and delivered in experienced centers.^[19]C4

Monitoring, supportive care, and safety

Early tumor shrinkage of 20% at the first assessment was examined as a prognostic marker in a real-world observational cohort of 128 patients with unresectable or recurrent squamous carcinoma treated with immune-checkpoint-inhibitor combinations; this evidence is hypothesis-generating rather than treatment-selecting.^[61] Immune-related adverse events and long-term survival were also assessed retrospectively in patients receiving immune-checkpoint-inhibitor combinations, but the single-center design limits causal interpretation.^[18]C4 ctDNA-guided response assessment is being studied in previously treated gastroesophageal adenocarcinoma, including baseline levels and early changes during trifluridine-tipiracil with or without bevacizumab; this does not yet establish ctDNA-guided treatment switching for esophageal cancer.^[12]B2b

Perioperative analgesic choices matter: a cohort of 557 patients undergoing gastroesophageal-junction cancer surgery evaluated ketorolac and other NSAIDs in relation to anastomotic leakage.^[11]B2b Endoscopic submucosal dissection remains a local-treatment context for selected superficial squamous lesions; a prospective study of 65 patients evaluated dexmedetomidine plus midazolam sedation without intubation.^[14]B2b Finally, GLP-1 receptor agonists should not be withheld solely because of presumed esophageal-cancer risk: a meta-analysis of 6 studies and 13,391 participants found a pooled relative risk of 0.46 (95% CI 0.22–0.97) versus control agents in adults with type 2 diabetes or obesity.^[1]A1a

Role and treatment settings

Concurrent chemoradiotherapy (CRT) combines radiosensitizing systemic therapy with definitive or neoadjuvant radiotherapy. In locally advanced unresectable esophageal cancer, definitive CRT (dCRT) is described as the standard treatment approach, with cisplatin plus 5-fluorouracil (5-FU) used as the reference chemotherapy regimen in the Japanese JCOG1510/TRIANgLE study design. ^[9]A1b A contemporary correlation analysis likewise evaluates event-free survival as a potential surrogate for overall survival specifically in randomized trials of dCRT for unresectable locally advanced disease, while recognizing overall survival as the definitive clinical endpoint. ^[21]A1a

For resectable locally advanced disease, neoadjuvant CRT (nCRT) is used before esophagectomy. A meta-analysis of 3 randomized trials involving 375 patients found that nCRT, compared with neoadjuvant chemotherapy (nCT), significantly increased the R0 resection and pathological complete response (pCR) rates. ^[3]A1a However, the same analysis found no significant difference in 3- or 5-year progression-free survival or 3- or 5-year overall survival, indicating that improved pathological response does not necessarily translate into a demonstrated long-term survival advantage over chemotherapy alone. ^[3]A1a

Chemotherapy strategies and investigational intensification

Cisplatin/5-FU is the conventional concurrent chemotherapy backbone cited for definitive CRT. ^[9]A1b JCOG1510 was designed as a phase III randomized study to test whether induction docetaxel, cisplatin, and 5-FU (DCF), followed by conversion surgery or dCRT, could improve overall survival compared with dCRT alone in locally advanced unresectable thoracic esophageal squamous cell carcinoma. ^[9]A1b The study planned enrollment of 230 patients across 47 Japanese institutions, with overall survival as the primary endpoint and progression-free survival, complete response to CRT, response to DCF, and adverse events as secondary endpoints. ^[9]A1b The supplied reference describes the trial design but does not provide comparative efficacy results. ^[9]A1b

In patients unable to receive cisplatin-based therapy, preoperative FOLFOX has been explored rather than concurrent CRT. A retrospective series evaluated oxaliplatin, leucovorin, and 5-FU in patients with resectable locally advanced squamous cell carcinoma who were at least 75 years old or had renal or cardiac dysfunction; the rationale was lower renal toxicity and avoidance of cisplatin-associated hydration requirements. ^[38]C4 This evidence concerns preoperative chemotherapy and should not be interpreted as proof of equivalence to cisplatin-based concurrent CRT. ^[38]C4

Superficial disease and selective CRT

CRT can also be used selectively after endoscopic treatment. In a prospective study of 176 patients with clinical T1b (SM1–2) N0M0 thoracic squamous cell carcinoma who underwent endoscopic resection, post-resection management was based on pathological findings. ^[24]B2b Patients with pT1a disease and negative margins without lymphovascular invasion received no additional therapy, whereas prophylactic CRT using 41.4 Gy to locoregional lymph nodes was used for selected pT1b or higher-risk pT1a disease. ^[24]B2b This selective strategy is distinct from routine definitive CRT for more advanced tumors. ^[24]B2b

Retrospective evidence also compares CRT with surgery after noncurative endoscopic submucosal dissection for superficial squamous cell carcinoma. One study included 60 patients, of whom 34 received adjuvant CRT and 26 underwent esophagectomy; it was designed to compare long-term oncologic outcomes, but the supplied abstract does not report the comparative outcome estimates. ^[62] Another retrospective series evaluated definitive-dose RT after endoscopic submucosal dissection in clinical T1N0M0 disease with pathological risk features, using 50–61.2 Gy, with or without chemotherapy, rather than the prophylactic 40–41.4 Gy approach reported in earlier CRT strategies. ^[31]B3b

Response assessment and prognostic considerations

Imaging may help assess response during or after CRT, but it does not replace pathological assessment when surgery is performed. A prospective cohort of 38 patients with squamous cell carcinoma undergoing concurrent CRT used serial diffusion-weighted MRI; at completion of treatment, 52.6% achieved complete response and 47.4% partial response by RECIST assessment. ^[28]C4 A 2024 meta-analysis reviewed MRI parameters for early response prediction in neoadjuvant therapy and concurrent CRT, but the supplied abstract does not provide pooled diagnostic estimates. ^[22]B2a

Interim 18F-FDG PET has also been studied during nCRT. A systematic review and meta-analysis evaluated changes in standardized uptake value for predicting pathological response, progression-free survival, and overall survival. ^[25]B2a An earlier meta-analysis similarly assessed PET performed during or after nCRT for prediction of primary-tumor pathological response. ^[26]B2a These studies support response assessment as an area of active investigation, but the supplied abstracts do not provide sufficient pooled performance values for clinical thresholds. ^{[25]B2a[26]B2a}

Weight loss during neoadjuvant chemotherapy is clinically relevant because tumor-related stenosis and treatment toxicity may impair intake. An exploratory analysis of OGSG1003 examined associations between treatment-related weight loss, postoperative infectious complications, and prognosis in patients receiving cisplatin/5-FU-based regimens with or without docetaxel. ^[7]B2b The supplied abstract does not report the quantitative associations; therefore, a specific weight-loss cutoff should not be inferred from this evidence. ^[7]B2b

Other concurrent-therapy contexts

Definitive CRT is also used for selected early-stage squamous cell carcinoma, although residual or recurrent local disease may occur after apparent complete remission. A retrospective study of 40 patients with cT1bN0M0 disease investigated endoscopic findings associated with non-radical cure after dCRT. ^[34]C4 Salvage CRT is another treatment context: a retrospective series of 147 patients treated for locoregional recurrence after surgery used RT alone at 60 Gy in 20 fractions or concurrent CRT at 60–70 Gy in 30–35 fractions. ^[32]C4

The supplied population-based Dutch study addresses treatment strategies for resectable esophageal or gastroesophageal-junction cancer with concurrent cervical lymph-node metastasis, including dCRT and neoadjuvant therapy followed by surgery; its abstract does not provide the comparative survival results. ^[27]B2b Advanced metastatic disease is outside the primary CRT framework: KEYNOTE-590 evaluated first-line pembrolizumab plus cisplatin/5-FU versus chemotherapy alone in previously untreated advanced cancer, not concurrent radiotherapy. ^[4]A1b Similarly, irinotecan/cisplatin and S-1/cisplatin-based studies evaluated systemic treatment for metastatic or advanced disease rather than CRT. ^{[15]B2b[17]A1b}

Practical interpretation

nCRT improves tumor sterilization and the likelihood of R0 resection compared with nCT, but a survival advantage has not been demonstrated in the cited randomized meta-analysis. ^[3]A1a dCRT remains the reference approach for unresectable locally advanced disease in the cited evidence, while induction chemotherapy, dose escalation, selective post-endoscopic CRT, salvage CRT, and imaging-guided response assessment represent setting-specific strategies requiring careful patient selection. ^{[9]A1b[21]A1a[24]B2b[31]B3b[32]C4}

Overview

Systemic chemotherapy selection depends on treatment intent, resectability, histology, comorbidity, and whether radiotherapy, surgery, or immune-checkpoint inhibition is incorporated. The evidence supplied includes perioperative, definitive chemoradiotherapy, unresectable/metastatic, and post-progression regimens, with several studies focused specifically on esophageal squamous-cell carcinoma (ESCC). ^{[3]A1a[9]A1b[15]B2b[38]C4[63]}

Neoadjuvant and perioperative chemotherapy

For locally advanced resectable disease, neoadjuvant chemotherapy (nCT) and neoadjuvant chemoradiotherapy (nCRT) are both evaluated approaches. A meta-analysis of 3 randomized trials including 375 patients found that adding radiotherapy to chemotherapy significantly increased R0 resection and pathological complete response rates compared with nCT alone; however, it did not significantly improve 3- or 5-year progression-free survival or overall survival. ^[3]A1a

In the Japanese OGSG1003 phase II trial, the neoadjuvant chemotherapy comparison was cisplatin plus fluorouracil (CF) with Adriamycin versus CF with docetaxel (DCF-related therapy) in patients with locally advanced ESCC. The exploratory analysis specifically examined treatment-associated weight loss and postoperative infectious complications, underscoring the importance of nutritional and toxicity monitoring during chemotherapy. ^[7]B2b Loss of skeletal muscle during neoadjuvant treatment was also associated with worse prognosis in a retrospective cohort of 115 patients undergoing neoadjuvant therapy and surgery. ^[40]B3b

For patients unable to receive cisplatin because of renal or cardiac dysfunction or advanced age, preoperative FOLFOX—oxaliplatin, leucovorin, and 5-fluorouracil—was evaluated retrospectively in resectable locally advanced ESCC. The regimen was administered every 2 weeks for 3 or 4 cycles and was selected because it has less renal toxicity and does not require the hydration associated with cisplatin-containing treatment. ^[38]C4

Adjuvant chemotherapy remains an area of uncertainty in node-positive ESCC. A randomized phase II study compared biweekly leucovorin/5-fluorouracil (LV5FU2) with FOLFOX for up to 8 cycles after curative R0 resection. Only 62 patients were randomized, so the study provides limited comparative evidence for selecting one regimen over the other. ^[8]B2b

Chemoradiotherapy regimens

The CROSS regimen consists of weekly carboplatin (area under the curve 2) plus paclitaxel 50 mg/m² with concurrent external-beam radiotherapy, followed by resection. In daily-practice data, treatment used 5 weekly courses and 23 fractions of 1.8 Gy; modified institutional protocols have also used radiation doses above 41.4 Gy with concurrent carboplatin/paclitaxel before esophagectomy. ^{[37]B3b[36]B2b}

For locoregional esophageal or gastroesophageal-junction cancer, retrospective comparative data evaluated carboplatin/paclitaxel versus cisplatin/fluorouracil in both trimodality therapy and definitive chemoradiotherapy. Carboplatin/paclitaxel-based nCRT followed by surgery was described as the standard approach at the reporting center, while cisplatin/fluorouracil remained an alternative for nCRT or definitive treatment. ^[63]

Definitive chemoradiotherapy with cisplatin plus 5-fluorouracil is the Japanese reference treatment for locally advanced unresectable thoracic ESCC. The JCOG1510 (TRIANgLE) phase III trial was designed to test induction docetaxel plus cisplatin and 5-fluorouracil (DCF), followed by conversion surgery or definitive chemoradiotherapy, against definitive cisplatin/5-fluorouracil chemoradiotherapy alone. ^[9]A1b

Capecitabine can substitute for infusional 5-fluorouracil in cisplatin-based definitive chemoradiotherapy. In a pilot study, patients received cisplatin 60 mg/m² on day 1 plus capecitabine 825 mg/m² twice daily on days 1–14 every 3 weeks, with radiotherapy to 60 Gy; two additional cycles of capecitabine/cisplatin were given after chemoradiotherapy. ^[42]C4

Unresectable or metastatic disease

Pembrolizumab plus chemotherapy is identified as recommended first-line therapy for unresectable advanced esophageal cancer in the Japanese cost-effectiveness analysis. ^[5]A1b In the Japanese subgroup of KEYNOTE-590, pembrolizumab 200 mg every 3 weeks for up to 35 cycles was combined with cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day and compared with placebo plus the same chemotherapy backbone. The study reported 5-year follow-up of previously untreated advanced esophageal cancer. ^[4]A1b

For metastatic, unresectable ESCC, irinotecan plus cisplatin was studied at irinotecan 65 mg/m² and cisplatin 30 mg/m² on days 1 and 8 of a 21-day cycle. In a phase II study of 27 patients, the objective response rate among 20 per-protocol patients was 30.0% with a 90% confidence interval of 13.2%–46.9%. ^[15]B2b

S-1 plus cisplatin was used as chemotherapy in a multicenter randomized study of advanced esophageal cancer; the experimental arm added Xiaoaiping. Both groups received treatment in 21-day cycles, with 62 patients per group. Because Xiaoaiping is an adjunctive intervention rather than a cytotoxic regimen, these results should not be interpreted as evidence that it replaces standard chemotherapy. ^[17]A1b

Real-world immune-checkpoint inhibitor combination therapy has also been reported for unresectable or metastatic esophageal cancer. In a retrospective cohort of 71 patients, the response rate among patients with measurable lesions was 58%, disease-control rate was 80%, and 5 patients (7.0%) underwent conversion surgery; grade ≥3 immune-related adverse events occurred in 13%, and one patient died from cholangitis. ^[39]C4

Later-line and investigational combinations

For refractory advanced gastroesophageal cancer, nivolumab was combined with irinotecan plus 5-fluorouracil (FOLFIRI) in a phase II study designed primarily to evaluate safety, treatment delays, dose reductions, response, overall survival, and progression-free survival. ^[41]B2b In gastroesophageal adenocarcinoma, commonly sequenced later-line options include ramucirumab plus paclitaxel, a taxane, irinotecan, or trifluridine/tipiracil; a retrospective sequencing study compared ramucirumab/paclitaxel followed by FOLFIRI or CAPEIRI with the reverse sequence. ^[64]C

Circulating tumor DNA-guided treatment monitoring remains investigational in previously treated metastatic gastroesophageal adenocarcinoma. A retrospective analysis assessed baseline ctDNA and early ctDNA changes during trifluridine/tipiracil with or without bevacizumab for prognosis, patient selection, and on-treatment response evaluation. ^[12]B2b

Practical safety considerations

Weight loss and skeletal-muscle depletion during neoadjuvant treatment are clinically relevant because both have been investigated in relation to postoperative complications and prognosis. Nutritional assessment, toxicity surveillance, and regimen adaptation are particularly important when treatment-related stenosis, adverse events, renal dysfunction, cardiac dysfunction, or older age limit chemotherapy tolerance. ^{[7]B2b[38]C4[40]B3b}

Scope and treatment context

Esophageal cancer comprises biologically heterogeneous squamous cell carcinoma (ESCC) and adenocarcinoma (EAC), and historical trials have frequently pooled histologies or grouped esophageal with gastroesophageal cancers, limiting precision treatment selection. ^[65]D Surgery remains the potentially curative treatment for appropriately fit patients with resectable disease. Trimodality therapy is generally used for localized ESCC, whereas preoperative chemoradiotherapy or perioperative chemotherapy is used for EAC; cervical esophageal cancer may require a different approach. ^[65]D

For operable disease, neoadjuvant chemoradiotherapy and perioperative chemotherapy are established treatment strategies. ESCC appears to respond better to neoadjuvant chemoradiotherapy than EAC, while both neoadjuvant chemoradiotherapy and perioperative chemotherapy are effective approaches for EAC. ^[49]D5 Chemoradiotherapy has been associated with higher pathologic complete response, node-negative resection, and R0-resection rates than neoadjuvant chemotherapy in reported trials, although the optimal strategy for EAC in terms of overall survival has remained uncertain. ^[49]D5

Immune checkpoint inhibitors in advanced disease

Immune checkpoint blockade, particularly inhibition of the PD-1/PD-L1 pathway, has become a major systemic treatment strategy for advanced esophageal cancer. Earlier evidence showed activity for pembrolizumab and nivolumab, while other immunotherapeutic approaches—including targeting chemokine receptors, oncolytic viruses, adoptive T-cell therapy, and cancer vaccines—were under development. ^[48]D5 The clinical benefit of checkpoint inhibition is not uniform, and PD-L1 expression has been identified as an important predictive biomarker; available evidence indicates that benefit is concentrated in selected patients, particularly those with higher PD-L1 expression. ^[47]D5

In first-line advanced disease, pembrolizumab plus chemotherapy is recommended in the treatment context evaluated by a Japanese cost-effectiveness study, which compared pembrolizumab plus chemotherapy with chemotherapy alone using a partitioned-survival model from the Japanese healthcare-payer perspective. ^[5]A1b The model incorporated parameters from a prior randomized controlled trial and a nationwide Japanese administrative database, and included a subgroup analysis of patients with PD-L1 combined positive score (CPS) ≥10. ^[5]A1b The economic value of pembrolizumab plus chemotherapy is therefore health-system and biomarker dependent; the cited study evaluated costs and quality-adjusted life-years rather than establishing a universal cost-effectiveness conclusion for all countries or patient groups. ^[5]A1b

The Japanese subgroup of KEYNOTE-590 provides extended follow-up of first-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated advanced esophageal cancer. Participants received pembrolizumab 200 mg every 3 weeks for up to 35 cycles or placebo, together with cisplatin 80 mg/m² and 5-fluorouracil 800 mg/m²/day. ^[4]A1b Overall survival and progression-free survival were investigator-assessed using RECIST version 1.1, with objective response rate and safety as secondary outcomes; the five-year analysis had a data cutoff of July 10, 2023. ^[4]A1b Earlier Japanese subgroup follow-up showed numerically improved overall and progression-free survival with pembrolizumab plus chemotherapy, and the cited report provides the extended five-year assessment. ^[4]A1b

A 2026 systematic review used matching-adjusted indirect comparisons to evaluate first-line serplulimab plus chemotherapy against other anti-PD-1/PD-L1 antibodies plus chemotherapy in treatment-naïve ESCC. ^[44]A1a Individual-patient data from ASTRUM-007 were reweighted to match aggregate data from seven comparator trials: CheckMate 648, ESCORT-1st, GEMSTONE-304, JUPITER-06, KEYNOTE-590, ORIENT-15, and RATIONALE-306. ^[44]A1a The analysis was designed to compare efficacy and safety across approved or clinically established antibody-based regimens while accounting for differences in baseline characteristics; because it was an indirect comparison rather than a head-to-head randomized trial, its findings should be interpreted as comparative evidence with residual uncertainty. ^[44]A1a

Adjuvant and neoadjuvant immunotherapy

For patients who undergo trimodality therapy, adjuvant nivolumab is recommended for those with residual pathologic disease rather than a pathologic complete response, according to the cited pharmacologic management review. ^[65]D The available evidence also describes neoadjuvant chemoradiotherapy-immunotherapy (NICRT) as a promising strategy for locally advanced ESCC, although the cited contemporary study was retrospective and multicenter rather than randomized. ^[66]D

In that study, 51 patients with histologically confirmed ESCC received NICRT followed by radical esophagectomy between October 2020 and October 2023. ^[66]D Tumor volumes were measured on computed tomography before and after treatment, and the tumor-volume change rate was correlated with survival outcomes; the study also examined the relationship between timing to surgery and prognosis. ^[66]D These findings support investigation of dynamic radiologic response and surgical timing as prognostic variables, but they do not establish a standard interval to surgery or prove that tumor-volume kinetics should independently guide treatment. ^[66]D

Biomarkers, body composition, and response monitoring

PD-L1 testing is clinically important because only a subset of patients with esophageal cancer benefit from PD-1 inhibition, and PD-L1 expression is currently the principal predictive biomarker discussed in the cited consensus evidence. ^[47]D5 Assay platforms, scoring methods, and clinically relevant thresholds may differ among agents and studies; therefore, PD-L1 results should be interpreted in the context of the specific treatment indication. ^[47]D5

Body composition may also influence outcomes during immune checkpoint inhibitor therapy. A Japanese database study of 111 patients with unresectable or recurrent esophageal cancer evaluated body mass index, waist circumference, psoas major muscle volume, and subcutaneous and visceral fat areas at ICI initiation in relation to disease-control rate and progression-free survival. ^[50]D5 These variables are potentially useful for risk assessment, but the cited study does not establish a body-composition threshold for selecting or withholding immunotherapy. ^[50]D5

Circulating tumor DNA is an emerging response-monitoring strategy, but the cited evidence concerns previously treated gastroesophageal adenocarcinoma rather than a validated esophageal-cancer immunotherapy biomarker. ^[12]B2b In a retrospective analysis linked to a randomized phase 2 trial of trifluridine-tipiracil with or without bevacizumab, baseline ctDNA and early ctDNA changes assessed using ctDNA-RECIST were evaluated for prognostic, patient-selection, and on-treatment monitoring value. ^[12]B2b ctDNA should therefore be regarded as investigational for guiding systemic treatment changes in esophageal cancer. ^[12]B2b

Targeted therapy and clinical interpretation

The references supplied for this section do not provide sufficient evidence to recommend a specific molecularly targeted drug for unselected esophageal cancer. Current evidence in this set primarily supports histology-aware, biomarker-informed immune checkpoint therapy, particularly PD-1/PD-L1 blockade combined with chemotherapy in advanced disease, while targeted agents, cellular therapies, vaccines, and oncolytic approaches remain areas of ongoing development or investigation. ^{[44]A1a[47]D5[48]D5[65]D}

Scope and evidence base

Toxicity management in esophageal cancer systemic therapy should be individualized according to treatment intent, regimen, comorbidity, nutritional and functional status, and the feasibility of subsequent therapy. The available evidence supplied here is predominantly retrospective and real-world; therefore, reported adverse-event rates should be interpreted as regimen- and population-specific rather than as universal estimates ^{[10]B2b[39]C4}. An older review described checkpoint-inhibitor treatment as an evolving component of esophageal and gastric cancer care and noted that, historically, systemic targeted therapies had generally provided limited benefit, with trastuzumab and ramucirumab identified as exceptions with relatively limited efficacy ^[67]D.

Immune-checkpoint inhibitor toxicity

In a multicenter real-world cohort of 184 patients receiving second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer, 14% experienced grade 3 or higher adverse events, and no treatment-related deaths were reported ^[10]B2b. These findings support the feasibility of nivolumab monotherapy in previously treated patients, while emphasizing the need for active surveillance for severe toxicity even when treatment is administered outside a clinical trial ^[10]B2b. The supplied abstract does not provide the organ-specific adverse-event spectrum, treatment interruptions, corticosteroid use, or hospitalization rates; these details should therefore not be inferred from the overall grade ≥3 rate ^[10]B2b.

Immune-checkpoint inhibitor combination therapy may produce a higher clinical response but requires particular vigilance for immune-related adverse events (irAEs). In a multicenter cohort of 71 patients treated with immune-checkpoint inhibitor combination therapy, 13% developed grade 3 or higher irAEs ^[39]C4. One patient (1.4%) died from cholangitis, demonstrating that serious or fatal complications can occur during combination treatment and that new hepatobiliary symptoms, fever, jaundice, abdominal pain, or biochemical abnormalities require prompt assessment ^[39]C4. The reported cohort also included successful conversion surgery in five patients (7.0%), making careful toxicity control especially relevant when treatment may be followed by surgery ^[39]C4.

A single-center retrospective study evaluated whether irAE occurrence was associated with progression-free survival, overall survival, and complete or partial response among patients receiving ICI combination regimens, including ICI plus chemotherapy or ICI plus ICI ^[18]C4. The supplied abstract identifies the comparison between patients with and without irAEs but does not provide the direction or magnitude of the survival association; consequently, irAEs should not be regarded as a validated surrogate for treatment benefit or deliberately induced to improve prognosis ^[18]C4.

Practical supportive-care priorities

Before and during systemic therapy, supportive care should include structured review of symptoms, performance status, hydration, oral intake, weight or body-composition changes, and laboratory abnormalities relevant to the selected regimen. Particular attention is warranted for suspected immune toxicity because severe irAEs occurred in 13% of patients receiving combination therapy in the available real-world cohort ^[39]C4. Cholangitis and other hepatobiliary complications must remain in the differential diagnosis of fever or liver-test abnormalities, particularly because one treatment-associated death from cholangitis was reported ^[39]C4.

Treatment decisions should also account for nutritional and body-composition status. In a retrospective study of 123 patients with locally advanced esophageal cancer treated with definitive chemoradiotherapy, CT images at the L3 level were used to assess muscularity and adiposity, and the study examined myosteatosis together with systemic inflammatory markers in relation to progression-free and overall survival ^[51]B3b. The study’s stated objective and findings concern prognostic associations rather than a proven toxicity-prevention intervention; therefore, CT-derived myosteatosis should be used as a risk-stratification and supportive-care consideration, not as a stand-alone indication to withhold systemic therapy ^[51]B3b. Nutritional assessment and early dietetic intervention are reasonable components of comprehensive care, although the supplied evidence does not establish a specific nutritional product, exercise prescription, or dose-adjustment algorithm ^[51]B3b.

Radiotherapy and multimodality considerations

Definitive radiotherapy remains relevant for selected early esophageal cancer, including T1–2N0M0 disease. A multicenter retrospective study of 196 patients compared definitive radiotherapy alone with radiochemotherapy and evaluated treatment technique, including three-dimensional conformal radiotherapy and intensity-modulated radiotherapy; the median planning target volume and gross tumor volume doses were both 60 Gy, with a median follow-up of 59.2 months ^[52]B3b. These data are prognostic and treatment-descriptive rather than a toxicity-management guideline, so they do not establish that one technique or combined-modality approach is universally safer ^[52]B3b.

Documentation and escalation

Document baseline symptoms and organ function, the regimen and exposure dates, severity and grade of each adverse event, suspected cause, interventions, treatment holds, and recovery. Escalate promptly when toxicity is severe, progressive, multisystem, or associated with fever, jaundice, respiratory symptoms, neurologic change, dehydration, or inability to maintain oral intake. The available studies support close monitoring and multidisciplinary management but do not provide a complete organ-specific algorithm for corticosteroids, immunosuppressants, rechallenge, or permanent ICI discontinuation ^{[10]B2b[18]C4[39]C4}.

Older, frail, and medically inoperable patients

Patients who are too old or frail for clinical-trial eligibility, or who decline esophagectomy, represent an important real-world population. In a single-institution retrospective cohort, patients treated with curative intent were managed with either trimodality therapy—neoadjuvant chemoradiation followed by esophagectomy—or definitive bimodality therapy without surgery. The study specifically evaluated differences in patient characteristics and outcomes between these approaches in routine practice. ^[56]B3b Definitive chemoradiotherapy is therefore a relevant treatment strategy when surgery is unsuitable, although retrospective comparisons are vulnerable to baseline selection differences. ^[56]B3b

Performance status is clinically important when selecting systemic therapy and concurrent chemoradiotherapy. A multicenter randomized study of Xiaoaiping combined with S-1 plus cisplatin enrolled patients with advanced esophageal cancer who had a Karnofsky Performance Status (KPS) of at least 60 and an expected survival of at least 3 months; patients received 21-day treatment cycles. ^[17]A1b The available report describes comparison with S-1 plus cisplatin alone, but the supplied evidence does not provide the complete efficacy or adverse-event results. ^[17]A1b In a retrospective cohort of patients undergoing concurrent chemoradiotherapy, clinical factors associated with treatment response and survival were investigated among 535 treated patients, with 493 having follow-up data. ^[60]D5 In patients with esophageal squamous cell carcinoma treated with radical radiotherapy, KPS, lymphatic metastasis, mid-treatment systemic immune-inflammation index (SII), and the pre-/post-radiotherapy SII ratio were identified as prognostic factors; the median overall survival was 649 days overall and 909 versus 466 days in the higher versus lower pre-/post-radiotherapy SII-ratio groups. ^[58]D5

Sarcopenia, cachexia, and nutritional vulnerability

Esophageal cancer is frequently accompanied by dysphagia, cachexia, and substantial loss of skeletal muscle. ^[53]B2a Preoperative sarcopenia can be quantified using the skeletal muscle index (SMI), typically measured on computed tomography at the level of the third lumbar vertebra; this measurement is described as reproducible and readily quantifiable. ^[53]B2a A systematic review and meta-analysis evaluated whether low preoperative SMI was associated with short-term postoperative complications after esophagectomy for esophageal neoplasia. ^[53]B2a These findings support incorporating body composition and nutritional assessment into preoperative risk stratification, optimization, and multidisciplinary treatment planning, particularly when neoadjuvant therapy is being considered. ^[53]B2a

Cervical lymph-node metastasis

Concurrent cervical lymph-node metastasis in thoracic esophageal cancer occupies a borderline position between locoregional and distant disease, and Western evidence guiding treatment selection is limited. ^[27]B2b A Dutch nationwide population-based cohort evaluated patients with resectable thoracic esophageal or gastroesophageal-junction cancer and concurrent cervical nodal metastasis. ^[27]B2b Recorded treatment strategies included definitive chemoradiotherapy, neoadjuvant therapy followed by surgery, and chemotherapy with or without limited radiotherapy of 30 Gy or less. ^[27]B2b Because this population has atypical staging and potentially curative as well as nonoperative treatment pathways, treatment should be individualized through multidisciplinary review of resectability, nodal distribution, systemic fitness, and treatment intent. ^[27]B2b

Definitive chemoradiotherapy and radiation-dose considerations

Definitive concurrent chemoradiotherapy has been evaluated in patients with stage II–III disease who do not undergo surgery. ^[55]B3b A retrospective study of 236 patients compared radiation doses below 60 Gy with doses of 60 Gy or higher; the median doses were 50.4 Gy and 63 Gy, respectively, and most patients received concurrent 5-fluorouracil plus cisplatin. ^[55]B3b The study examined the relationship between radiation dose and locoregional control, but the supplied abstract does not include the comparative outcome results. ^[55]B3b Dose selection should consequently be interpreted in the context of institutional protocols, tumor anatomy, normal-tissue constraints, and the patient’s ability to complete combined-modality treatment. ^[55]B3b

Unresectable, recurrent, or metastatic disease

Second-line nivolumab monotherapy has real-world activity in unresectable or metastatic esophageal cancer. In a multicenter retrospective cohort of 184 patients treated between March 2021 and December 2022, the response rate among 128 patients with measurable lesions was 23%, the disease-control rate in the full cohort was 45%, and grade 3 or higher adverse events occurred in 14%; no treatment-related deaths were reported. ^[10]B2b The study also assessed prognostic factors, long-term survival, and subsequent third-line treatment. ^[10]B2b

Immune-checkpoint inhibitor (ICI) combination therapy has also been evaluated in routine practice. In a multicenter cohort of 71 patients with unresectable or metastatic esophageal cancer, the response rate among patients with measurable lesions was 58%, the disease-control rate was 80%, and 5 patients (7.0%) underwent successful conversion surgery. ^[39]C4 Grade 3 or higher immune-related adverse events occurred in 13%, and one patient (1.4%) died from cholangitis. ^[39]C4 A separate retrospective study examined whether immune-related adverse events were associated with progression-free survival, overall survival, and complete or partial response among patients receiving ICI combination regimens for unresectable advanced or recurrent disease. ^[18]C4

For refractory advanced gastroesophageal cancer, nivolumab combined with irinotecan and 5-fluorouracil (FOLFIRI) was investigated because both anti-PD-1 therapy and irinotecan-based treatment have limited activity in selected previously treated populations. ^[41]B2b The study’s primary endpoint was safety, including toxicity, dose delays, and dose reductions; response, overall survival, and progression-free survival were secondary endpoints. ^[41]B2b This approach should be regarded as investigational or highly individualized because the supplied evidence is not a randomized esophageal-cancer comparison. ^[41]B2b

Ramucirumab plus paclitaxel is an established second-line strategy in metastatic gastric and gastroesophageal-junction adenocarcinoma based on the RAINBOW experience, although the cited real-world study evaluated a modified biweekly schedule. ^[57]B3b In that retrospective series, 129 patients received ramucirumab and paclitaxel every 2 weeks, with overall survival, progression-free survival, response, and safety assessed. ^[57]B3b

Dysphagia after radiotherapy

Patients with malignant obstruction or fistula after radiotherapy may require endoscopic palliation. In a retrospective series of 83 patients treated with a low-radial-force self-expandable metallic stent, 32 had prior radiotherapy and 51 did not. ^[59]D5 Major adverse-event rates were similar in the radiotherapy and non-radiotherapy groups (6.3% versus 5.9%, respectively; p=0.95). ^[59]D5 Low-radial-force stenting may therefore be considered when palliation is necessary after radiotherapy, with individualized assessment of obstruction, fistula, anatomy, and procedural risk. ^[59]D5

Surgical reconstruction and postoperative complications

Postoperative morbidity remains relevant when systemic therapy is integrated with esophagectomy. A systematic review and meta-analysis specifically assessed the effect of preoperative sarcopenia on complications after esophagectomy. ^[53]B2a Anastomotic stricture is another postoperative concern; a retrospective study of 70 patients undergoing transthoracic esophagectomy with cervical circular-stapled esophagogastrostomy compared a novel keyhole procedure, which enlarges the circular-stapler opening with a linear stapler, with the conventional approach, using stricture within 180 days as the primary outcome. ^[54]B3b This technical study informs reconstruction rather than systemic-treatment selection, but it is relevant to treatment planning because postoperative recovery and complication risk can affect the feasibility and timing of adjuvant therapy. ^[54]B3b

Part of the Esophageal Cancer family. Cross-cutting management split across dedicated child pages:

• Esophageal Cancer , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
• Esophageal Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
• Esophageal Cancer Radiation Management , EBRT + image-guided brachytherapy + concurrent chemoradiation, dose / fractionation, OAR constraints
• Esophageal Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
• Esophageal Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
• Esophageal Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease

Pearl: Use these links to hop between management modalities; the parent Esophageal Cancer page carries diagnosis + staging that informs every decision here.